ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Cognitive Dysfunction
Alzheimer Disease
Blood-Brain Barrier
Apolipoprotein E, Deficiency or Defect of
Brain Aging
Fatty Acids, Omega-3

Interventions

DRUG: Alpha-Linolenic Acid (2.6 g/day)
DIETARY_SUPPLEMENT: Placebo Control Group

Sponsor

Michal Schnaider Beeri, Ph.D.